ZIRGAN Dosing and Handling
ZIRGAN Dosing and Handling
Recommended dosing regimen1:
- One drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals
- Followed by 1 drop 3 times per day for 7 days
ZIRGAN is supplied as 5 grams of a topical ophthalmic gel containing 0.15% of ganciclovir in a polycoated aluminum tube.1
NDC number: 24208-535-35
There is no need for refrigeration (store between 59°F and 77°F). Do not freeze.1
Accessing ZIRGAN
See if your eligible patients are covered with Bausch + Lomb’s formulary tool.
Check our formulary toolHelp eligible patients save on ZIRGAN
Learn about a special savings offer from Bausch + Lomb.
See the detailsIndication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Click here for full Prescribing Information for ZIRGAN®.
ZIRGAN® is a trademark of Laboratoires Théa Corporation used under license.
Reference: 1. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated.
Indication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Click here for full Prescribing Information for ZIRGAN®.
ZIRGAN® is a trademark of Laboratoires Théa Corporation used under license.
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: